In this study, the anti-tumor effects by targeting VSIG4+ TAMs were investigated using VSIG4-knockout (KO) mouse models and an anti-VSIG4 antibody, especially in two extremely aggressive cancers, PDAC and ATC. The gene discussed is VSIG4; the disease is neoplasm.